All News

The findings could additionally help researchers understand the fundamental biology of how coronavirus disease 2019 (COVID-19) spreads from the lungs to the body.

The FDA has approved mepolizumab for the treatment of hypereosinophilic syndrome.

Inflammation caused by rheumatoid arthritis may increase the risk of type 2 diabetes.

The FDA has approved tofacitinib for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis.

Survey shows that having a pet was linked to maintaining better mental health and reduced loneliness, with 90% of the 6000 participants from the UK saying they had at least 1 pet.

Cefiderocol approved for the treatment with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

The Provider Relief Fund, as part of the CARES Act, was an important stopgap for many health care providers across the country, but details on reporting requirements and timing have been elusive.

In 1989, more than 1500 young, healthy people started experiencing mysterious symptoms that included unusual skin rashes, muscle pains, dramatic eosinophilia, and tightening of the skin.

Pregnancy may help put off the onset of multiple sclerosis symptoms by more than 3 years.

This week on Pharmacy Times, there are a number of hot topics that we will be posting throughout the week.

Children with a previous diabetes diagnosis showed lower performances compared with newly diagnosed children, suggesting that the deficits may worsen over time.

Less than 10% of the people who should be taking pre-exposure prophylaxis for HIV are taking the medications.

Using a 3D model, investigators found a soy-based compound was effective in treating bone cancer.

Though more research is needed, reactivation of the varicella-zoster virus may be caused by a decrease in absolute lymphocytes caused by COVID-19.

New drug application been submitted for TLX591-CDx (illumet), a radiopharmaceutical product that targets prostate-specific membrane antigen for the imaging of prostate cancer.

It is especially important to better understand the interactions between COVID-19 and acute respiratory distress syndrome.

Two newly discovered antibodies could help in the development of a universal flu vaccine.

Researchers found the largest decreases for heart attack risk among women, which may be because of greater attention paid to women’s heart health in recent decades.

Insurance companies are currently investigating the option of modifying which medications they will cover for HIV pre-exposure prophylaxis (PrEP) therapy, with broad implications for patient access.

In the 18th century, how was tobacco smoke administered to resuscitate drowning victims?

A new study found that hypertension is a common comorbidity in patients with COVID-19.

Researchers at Duke University have found that the efficacy of a 2-pronged type 2 diabetes (T2D) treatment increases when the drugs are linked by a heat-sensitive tether rather than simply being concurrently administered, according to a press release.

Top news of the week from Pharmacy Times®.

Camber Pharmaceuticals launches Dimethyl Fumarate DR capsules, the generic version of Tecfidera® capsules, which is indicated for the treatment of relapsing forms of multiple sclerosis.

The FDA has granted fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors have high DKK1 expression.

An overview of the most common human resources problems that pharmacies face and the proactive steps that pharmacies can take to avoid these problems.

A combination treatment was found to be associated with significantly less weight gain and smaller increases in waist circumference than treatment with olanzapine alone.

The Medication Management Module is a solution for pharmacists to assess each patient’s medication and ensure it is appropriate, effective, and safe given the patient’s comorbidities and medication plan.

A trial will enroll up to 60,000 participants to assess the safety and efficacy of a COVID-19 vaccine candidate that only requires a single dose.

A recent study found that patients on immunosuppressive therapy for common skin and rheumatic diseases, such as psoriasis and rheumatoid arthritis, are not at an increased risk for contracting COVID-19.